Literature DB >> 30498624

Tumor-infiltrating regulatory T cells: origins and features.

Guoping Deng1.   

Abstract

Tumor cells evolve multiple sophisticated mechanisms to escape immune surveillance, one of which is to establish tolerogenic microenvironment by recruiting certain immune suppressive cells such as regulatory T cells (Tregs) and myeloid derived suppressor cells (MDSCs). Tregs are subpopulation of CD4+ T cells, which specialize in suppressing immune responses and preventing autoimmune damage to collateral tissue. Emerging evidence suggests that Treg cell number increases in various types of cancer, which correlates with tumor grade and poor patient prognosis. This review will focus on discussion of the origins and features of tumor-infiltrating Treg cells. Ultimately, these features may provide insight into potential therapeutic intervention by targeting Treg cells to invigorate immune response against tumor.

Entities:  

Keywords:  Regulatory T cells; Treg metabolism; Treg origin; tumor microenvironment

Year:  2018        PMID: 30498624      PMCID: PMC6261843     

Source DB:  PubMed          Journal:  Am J Clin Exp Immunol


  41 in total

1.  Ccl22 Diverts T Regulatory Cells and Controls the Growth of Melanoma.

Authors:  Jared Klarquist; Kristen Tobin; Peyman Farhangi Oskuei; Steven W Henning; Manuel F Fernandez; Emilia R Dellacecca; Flor C Navarro; Jonathan M Eby; Shilpak Chatterjee; Shikhar Mehrotra; Joseph I Clark; I Caroline Le Poole
Journal:  Cancer Res       Date:  2016-09-12       Impact factor: 12.701

2.  T cell receptor stimulation-induced epigenetic changes and Foxp3 expression are independent and complementary events required for Treg cell development.

Authors:  Naganari Ohkura; Masahide Hamaguchi; Hiromasa Morikawa; Kyoko Sugimura; Atsushi Tanaka; Yoshinaga Ito; Motonao Osaki; Yoshiaki Tanaka; Riu Yamashita; Naoko Nakano; Jochen Huehn; Hans Joerg Fehling; Tim Sparwasser; Kenta Nakai; Shimon Sakaguchi
Journal:  Immunity       Date:  2012-11-01       Impact factor: 31.745

3.  Membrane-organizing protein moesin controls Treg differentiation and antitumor immunity via TGF-β signaling.

Authors:  Ephraim A Ansa-Addo; Yongliang Zhang; Yi Yang; George S Hussey; Breege V Howley; Mohammad Salem; Brian Riesenberg; Shaoli Sun; Don C Rockey; Serhan Karvar; Philip H Howe; Bei Liu; Zihai Li
Journal:  J Clin Invest       Date:  2017-03-13       Impact factor: 14.808

4.  Expression of RORγt marks a pathogenic regulatory T cell subset in human colon cancer.

Authors:  Nichole R Blatner; Mary F Mulcahy; Kristen L Dennis; Denise Scholtens; David J Bentrem; Joseph D Phillips; Soo Ham; Barry P Sandall; Mohammad W Khan; David M Mahvi; Amy L Halverson; Steven J Stryker; Anne-Marie Boller; Ashima Singal; Rebekka K Sneed; Bara Sarraj; Mohammed Javeed Ansari; Martin Oft; Yoichiro Iwakura; Liang Zhou; Andreas Bonertz; Philipp Beckhove; Fotini Gounari; Khashayarsha Khazaie
Journal:  Sci Transl Med       Date:  2012-12-12       Impact factor: 17.956

5.  Instability of Helios-deficient Tregs is associated with conversion to a T-effector phenotype and enhanced antitumor immunity.

Authors:  Hidetoshi Nakagawa; Jessica M Sido; Edwin E Reyes; Valerie Kiers; Harvey Cantor; Hye-Jung Kim
Journal:  Proc Natl Acad Sci U S A       Date:  2016-05-16       Impact factor: 11.205

6.  DNA demethylation in the human FOXP3 locus discriminates regulatory T cells from activated FOXP3(+) conventional T cells.

Authors:  Udo Baron; Stefan Floess; Georg Wieczorek; Katrin Baumann; Andreas Grützkau; Jun Dong; Andreas Thiel; Tina J Boeld; Petra Hoffmann; Matthias Edinger; Ivana Türbachova; Alf Hamann; Sven Olek; Jochen Huehn
Journal:  Eur J Immunol       Date:  2007-09       Impact factor: 5.532

7.  Local and systemic induction of CD4+CD25+ regulatory T-cell population by non-Hodgkin lymphoma.

Authors:  Sajjan Mittal; Neil A Marshall; Linda Duncan; Dominic J Culligan; Robert N Barker; Mark A Vickers
Journal:  Blood       Date:  2008-02-27       Impact factor: 22.113

8.  IDO expression in brain tumors increases the recruitment of regulatory T cells and negatively impacts survival.

Authors:  Derek A Wainwright; Irina V Balyasnikova; Alan L Chang; Atique U Ahmed; Kyung-Sub Moon; Brenda Auffinger; Alex L Tobias; Yu Han; Maciej S Lesniak
Journal:  Clin Cancer Res       Date:  2012-08-29       Impact factor: 12.531

9.  Suppressive IL-17A+Foxp3+ and ex-Th17 IL-17AnegFoxp3+ Treg cells are a source of tumour-associated Treg cells.

Authors:  Stephanie Downs-Canner; Sara Berkey; Greg M Delgoffe; Robert P Edwards; Tyler Curiel; Kunle Odunsi; David L Bartlett; Nataša Obermajer
Journal:  Nat Commun       Date:  2017-03-14       Impact factor: 14.919

10.  Conversion of peripheral CD4+CD25- naive T cells to CD4+CD25+ regulatory T cells by TGF-beta induction of transcription factor Foxp3.

Authors:  WanJun Chen; Wenwen Jin; Neil Hardegen; Ke-Jian Lei; Li Li; Nancy Marinos; George McGrady; Sharon M Wahl
Journal:  J Exp Med       Date:  2003-12-15       Impact factor: 14.307

View more
  22 in total

1.  Murine Mammary Carcinoma Induces Chronic Systemic Inflammation and Immunosuppression in BALB/c Mice.

Authors:  Dasha Fuentes; Alejandro Cabezas-Cruz; Circe Mesa; Tania Carmenate; Darel Martínez; Anet Valdés-Zayas; Enrique Montero; Rolando Pérez
Journal:  J Breast Cancer       Date:  2022-04-26       Impact factor: 2.922

Review 2.  Recent Progress in the Synergistic Combination of Nanoparticle-Mediated Hyperthermia and Immunotherapy for Treatment of Cancer.

Authors:  Zachary R Stephen; Miqin Zhang
Journal:  Adv Healthc Mater       Date:  2020-11-25       Impact factor: 9.933

3.  Understanding and Targeting Human Cancer Regulatory T Cells to Improve Therapy.

Authors:  H Ryan Kolb; Nicholas Borcherding; Weizhou Zhang
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 3.650

Review 4.  Perspectives in Manipulating EVs for Therapeutic Applications: Focus on Cancer Treatment.

Authors:  Katarzyna Nazimek; Krzysztof Bryniarski
Journal:  Int J Mol Sci       Date:  2020-06-29       Impact factor: 5.923

5.  Autologous Hematopoietic Stem Cells Are a Preferred Source to Generate Dendritic Cells for Immunotherapy in Multiple Myeloma Patients.

Authors:  Prajakta Shinde; Sameer Melinkeri; Manas Kumar Santra; Vaijayanti Kale; Lalita Limaye
Journal:  Front Immunol       Date:  2019-05-21       Impact factor: 7.561

Review 6.  Foxp3 Post-translational Modifications and Treg Suppressive Activity.

Authors:  Guoping Deng; Xiaomin Song; Shigeyoshi Fujimoto; Ciriaco A Piccirillo; Yasuhiro Nagai; Mark I Greene
Journal:  Front Immunol       Date:  2019-10-18       Impact factor: 7.561

7.  Overcoming Intrinsic Doxorubicin Resistance in Melanoma by Anti-Angiogenic and Anti-Metastatic Effects of Liposomal Prednisolone Phosphate on Tumor Microenvironment.

Authors:  Emilia Licarete; Valentin Florian Rauca; Lavinia Luput; Denise Drotar; Ioana Stejerean; Laura Patras; Bogdan Dume; Vlad Alexandru Toma; Alina Porfire; Claudia Gherman; Alina Sesarman; Manuela Banciu
Journal:  Int J Mol Sci       Date:  2020-04-23       Impact factor: 5.923

8.  Data Driven Mathematical Model of FOLFIRI Treatment for Colon Cancer.

Authors:  Aparajita Budithi; Sumeyye Su; Arkadz Kirshtein; Leili Shahriyari
Journal:  Cancers (Basel)       Date:  2021-05-27       Impact factor: 6.639

Review 9.  Genetic Alterations in Gliomas Remodel the Tumor Immune Microenvironment and Impact Immune-Mediated Therapies.

Authors:  Maria B Garcia-Fabiani; Santiago Haase; Andrea Comba; Stephen Carney; Brandon McClellan; Kaushik Banerjee; Mahmoud S Alghamri; Faisal Syed; Padma Kadiyala; Felipe J Nunez; Marianela Candolfi; Antonela Asad; Nazareno Gonzalez; Marisa E Aikins; Anna Schwendeman; James J Moon; Pedro R Lowenstein; Maria G Castro
Journal:  Front Oncol       Date:  2021-06-08       Impact factor: 5.738

10.  The resveratrol analogue, HS‑1793, enhances the effects of radiation therapy through the induction of anti‑tumor immunity in mammary tumor growth.

Authors:  Joong Sun Kim; Soo Kyung Jeong; Su Jung Oh; Chang Geun Lee; Yeong Rok Kang; Wol Soon Jo; Min Ho Jeong
Journal:  Int J Oncol       Date:  2020-03-19       Impact factor: 5.650

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.